Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCasós Vásquez, Kelly
dc.contributor.authorFerrer Curriu, Gemma
dc.contributor.authorSoler-Ferrer, Paula
dc.contributor.authorPérez González, MªLlanos
dc.contributor.authorPermanyer Buada, Eduard
dc.contributor.authorBlasco Lucas, Arnau
dc.contributor.authorGracia Baena, Juan Manuel
dc.contributor.authorCastro Alba, Miguel Angel
dc.contributor.authorSureda Barbosa, José Carlos
dc.contributor.authorBarquinero Mañez, Jordi
dc.contributor.authorGaliñanes Hernández, Manuel
dc.date.accessioned2021-04-27T11:39:51Z
dc.date.available2021-04-27T11:39:51Z
dc.date.issued2017-04-05
dc.identifier.citationCasós K, Ferrer-Curriu G, Soler-Ferrer P, Pérez ML, Permanyer E, Blasco-Lucas A, et al. Response of the human myocardium to ischemic injury and preconditioning: The role of cardiac and comorbid conditions, medical treatment, and basal redox status. Eckle T, editor. PLoS One. 2017 Apr 5;12(4):e0174588.
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/11351/5914
dc.descriptionAortic valve; Ischemia; Myocardium
dc.description.abstractBackground The diseased human myocardium is highly susceptible to ischemia/reoxygenation (I/R)-induced injury but its response to protective interventions such as ischemic preconditioning (IPreC) is unclear. Cardiac and other pre-existing clinical conditions as well as previous or ongoing medical treatment may influence the myocardial response to I/R injury and protection. This study investigated the effect of both on myocardial susceptibility to I/R-induced injury and the protective effects of IPreC. Methods and results Atrial myocardium from cardiac surgery patients (n = 300) was assigned to one of three groups: aerobic control, I/R alone, and IPreC. Lactate dehydrogenase leakage, as a marker of cell injury, and cell viability were measured. The basal redox status was determined in samples from 90 patients. The response to I/R varied widely. Myocardium from patients with aortic valve disease was the most susceptible to injury whereas myocardium from dyslipidemia patients was the least susceptible. Tissue from females was better protected than tissue from males. Myocardium from patients with mitral valve disease was the least responsive to IPreC. The basal redox status was altered in the myocardium from patients with mitral and aortic valve disease. Conclusions The response of the myocardium to I/R and IPreC is highly variable and influenced by the underlying cardiac pathology, dyslipidemia, sex, and the basal redox status. These results should be taken into account in the design of future clinical studies on the prevention of I/R injury and protection.
dc.language.isoeng
dc.publisherPublic Library of Science
dc.relation.ispartofseriesPLoS ONE;12(4)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMalalties coronàries - Tractament
dc.subject.meshMyocardial Ischemia
dc.subject.meshIschemic Preconditioning, Myocardial
dc.titleResponse of the human myocardium to ischemic injury and preconditioning: The role of cardiac and comorbid conditions, medical treatment, and basal redox status
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1371/journal.pone.0174588
dc.subject.decsisquemia miocárdica
dc.subject.decsprecondicionamiento isquémico miocárdico
dc.relation.publishversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0174588
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Casós K, Ferrer-Curriu G, Soler-Ferrer P, Pérez ML] Grup de Teràpia repadora del cor, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Permanyer E, Blasco-Lucas A, Gracia-Baena JM, Castro MA, Sureda C] Servei de Cirurgia Cardíaca, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Barquinero J] Grup de Teràpia Gènica i Cel·lular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Galiñanes M] Grup de Teràpia repadora del cor, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Cirurgia Cardíaca, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid28380047
dc.identifier.wos000399353500053
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/1PN/2008-2011/PI12%2F00119
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record